MRNA Stock: Buy or Sell? Price Target & Forecast

Analyses / MRNA

MRNA Moderna Inc As of Jul 29, 2026

$55.81

Biotech recovery play with margin headwinds; valuation compressed vs. historical, insider mixed signals.

Setup: Recovery / Turnaround Confidence: 55 Horizon: 6-12 months Risk: High Category: Biotechnology

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals MRNA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Stock near 52-week lows (35% below high); mRNA platform optionality across RSV, flu, cancer; strong balance sheet (3.29x current ratio); revenue recovery thesis if pipeline advances; insider buy count (91) positive vs. sell count (124). Potential re-rating if margins inflect.

▼ Bear Case

Revenue collapsed -53% YoY; operating margin -158%, net margin -145% — company deeply unprofitable. P/S 11.3x historically elevated for biotech in turnaround. No earnings or forward guidance in data. Insider sells outnumber buys 1.36x — potential pessimism among management. Execution risk on pipeline critical.

Valuation

Compressed vs. historical, but unprofitable — traditional multiples unreliable. — score 58/100

P/B 1.33x fair to cheap for biotech; P/S 11.3x appears elevated but normalized for pipeline-dependent firms in turnaround. Price-to-FCF 4.8x is distorted by negative earnings. Absence of P/E and forward P/E signals market unwilling to model near-term profitability. Margin recovery is pricing swing factor.

Technical Levels

Support · $53.35 (Recent intraday low) · $50.00 (Psychological support / entry thesis level) · $46.00 (Stop-loss / major breakdown risk) · $22.28 (52-week low (capitulation zone))

Resistance · $58.00 (Short-term resistance / upper entry zone) · $65.00 (Intermediate resistance) · $72.00 (Target-price level / re-rating threshold) · $85.60 (52-week high / major technical level)

RSI: Data unavailable

Financial Health

Score 72/100. Balance sheet fortress: 3.3x current ratio, solid liquidity. Book value/share near current price suggests P/B ~1.3x is fair on tangible assets. However, operating and net losses are severe; company is burning cash at scale. Sustainability depends on pipeline progression or additional capital raise.

Catalysts

Quarterly earnings / revenue guidance update	Next earnings report (Q2 or Q3 2024, timing TBD)	High. Margin inflection or stabilization would be bullish; further revenue declines or cash burn miss would pressure stock.
RSV or flu vaccine clinical / regulatory milestone	Q3–Q4 2024 possible	High. Approval or Phase 3 success could re-rate sentiment and justify higher valuation.
Cancer immunotherapy program update	H2 2024 or later	Medium-to-High. TAM expansion beyond vaccines; partnership or internal advance could unlock optionality.
Strategic partnership or M&A	Uncertain	Medium-to-High. Licensing deals or acquisition interest could de-risk cash burn and validate platform.

Risk Flags

P/E and forward P/E unavailable; profitability metrics missing or negative — valuation difficult to pin down.

Revenue YoY collapse (-53%) is severe; sustainability of turnaround unproven. No forward guidance or earnings estimate in data.

Negative EV/EBITDA (-7.1x) reflects operating losses; cash burn trajectory unclear without detailed cash flow statement.

Insider activity mixed: more sells than buys; could signal uncertainty at management level.

Stock peaked 85.6 in 52-week range; -35% from high suggests sentiment inflection — risk of further downside if pipeline stumbles.

See MRNA's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock MRNA free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

MRNA FAQ

Is MRNA a buy right now?

Moderna Inc's current read is a Recovery / Turnaround setup with 55 confidence over a 6-12 months horizon. Valuation: Compressed vs. historical, but unprofitable — traditional multiples unreliable.. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is MRNA overvalued?

Compressed vs. historical, but unprofitable — traditional multiples unreliable. (valuation score 58/100). P/B 1.33x fair to cheap for biotech; P/S 11.3x appears elevated but normalized for pipeline-dependent firms in turnaround. Price-to-FCF 4.8x is distorted by negative earnings. Absence of P/E and forward P/E signals market unwilling to model near-term profitability. Margin recovery is pricing swing factor.

What are the risks of buying MRNA?